Not sure how we missed this one earlier (the press release on their website is dated 8/27/07), but how cool is this?!
Latest Press Release
[b]Renal Solutions Announces Collaborative Agreement with Innovative BioTherapies
– Data Will Provide Due Diligence Necessary for Future Development of a Wearable Renal Replacement Device --[/b]
WARRENDALE, PA August 27, 2007 – Renal Solutions, Inc., the exclusive provider of Advanced Sorbent Therapy™ products and services for the treatment of chronic and acute renal failure, announces the signing of a collaborative agreement with Innovative BioTherapies, Inc. (IBT) and the University of Michigan for development of a wearable renal replacement device.
Through the terms of the agreement, Renal Solutions and David Humes, M.D. of IBT will explore the ways that sorbent therapy from Renal Solutions, which uses just six liters of drinking water to deliver a full dialysis treatment, can be combined with the stem cell technologies of Innovative BioTherapies and the University of Michigan to ultimately develop a highly portable, wearable device for renal replacement. This exploration will allow for IBT to use the Allient® Sorbent Hemodialysis System for evaluating the effectiveness of providing continuous dialytic therapy. Using animal models, the collaboration will further evaluate the metabolic consequences of a renal tubule cell device, including measurement of inflammatory response. The data resulting from these studies will greatly assist both companies in moving forward with plans for a wearable renal replacement device.
“We are very pleased to be working with Dr. Humes to combine the benefits of sorbent therapy with the exciting possibilities of the bioartificial kidney,” said Peter M. DeComo, Chairman and CEO of Renal Solutions. “The convergence of sorbent technology’s ability to use small amounts of drinking water with the breakthrough technology provided by living renal cells presents exciting possibilities for the miniaturization and development of a portable, wearable device,” Mr. DeComo stated.
“Cell-based therapies show tremendous potential for revolutionizing renal replacement therapy,” said Dr. Humes, President of IBT and professor of internal medicine at the University of Michigan, Ann Arbor. “The low water requirement of RSI’s dialysis technology combined with renal cells makes the prospect of a portable, wearable bioartificial kidney for full renal replacement therapy feasible,” he added.
About Renal Solutions, Inc
Renal Solutions, Inc., a medical device and health-care service company, is commercializing the Allient® Sorbent Hemodialysis System, a revolutionary technology/service solution for the chronic and acute dialysis market. The Allient System using Advanced Sorbent Therapy™ opens new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased transportability, flexibility and ease of system use.
About Innovative BioTherapies, Inc.
The bioartificial kidney research originated at the University of Michigan in Ann Arbor, under the leadership of Dr. Humes. Key to its development has been the renal tubule assist device (RAD), which is filled with living renal proximal tubule cells, grown in the lab from salvaged adult stem cells taken from unusable donor kidneys. In a Phase II controlled study in the intensive care unit (ICU) setting in late 2005, the RAD was shown to reduce 28-day mortality from 61 percent to 34 percent. This research is an important step in making a wearable bioartificial kidney a reality.www.innbio.com
This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for the Company’s products/services and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.
Zero to Five, LLC
Marketing Director, Renal Solutions, Inc.
(724) 772-6900 ext. 109